TaflupROSt 是一种抗青光眼前列腺素（PG）类似物。

Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.

Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern [1]. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile [2]. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma [3].

209860-87-7

C25H34F2O5

452.53

AFP-168;他氟前列素;MK2452

DMSO:250 mg/mL (552.45 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years